TELA

TELA Bio, Inc. [TELA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TELA Stock Summary

In the News

TELA Financial details

Company Rating
-
Market Cap
121.28M
Income
-48.68M
Revenue
58.45M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
227
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-3.95
Forward P/E
-
PEG
1.93
P/S
3.39
P/B
5.89
P/C
-
P/FCF
-5.33
Quick Ratio
4.32
Current Ratio
5.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.17
EPS next Y
-
EPS next Q
-
EPS this Y
-25.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-2.03%
Revenue last 5Y
30.5%
Revenue Q/Q
12.93%
EPS Q/Q
17.78%
-
-
-
-
SMA20
-0.86%
SMA50
-23.84%
SMA100
-42.21%
Inst Own
-
Inst Trans
-
ROA
-52%
ROE
-207%
ROC
-0.57%
Gross Margin
69%
Oper. Margin
-78%
Profit Margin
-86%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.235-11.26
52W High
-89.55%
52W Low
-71.25%
RSI
46.02
Rel Volume
1.01
Avg Volume
110.67K
Volume
112.26K
Perf Week
0%
Perf Month
-11.54%
Perf Quarter
-40.41%
Perf Half Y
-38.5%
-
-
-
-
Beta
0.947
-
-
Volatility
0.02%, 0.06%
Prev Close
1.77%
Price
1.15
Change
-3.36%

Something similar

Top by Market Cap
BRYN.DE
GOOG
MSF.DE
BRH.DE
BRK-B
Same Sector
TNXP
FORTIS.NS
POAI
CTXR
ABOS
Same Price Range
SKC.NZ
CY6U.SI
8375.HK
ORTI-A.ST
AUTL
Similar Market Cap
VOR
LTVL.DE
CIL
BPRN
1580.HK

Company Profile

Healthcare Medical - Devices
  • Volume Average 110.67K
  • Market Capitalization 121.28M
  • Employee 227
  • CEO Mr. Antony Koblish
  • Headquarters Malvern,PA,US
  • IPO Date 2019-11-08
  • Website https://www.telabio.com

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.